TrialHematological oncology2021

Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study.

Francesco Passamonti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.